IB Net Payout Yields Model

Hims & Hers: Sell-Off Opportunity

  • Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments here » 

Update - July 28, 2023 

Cowen with a bull call on Hims with a price target of $11 after the stock recently traded at $12. Nice the greatest bull call, but it sure beats the short report. 

  • TD Cowen initiated its coverage of the digital healthcare platform Hims & Hers Health (NYSE:HIMS) with an Outperform rating and a $11 per share target on Friday, citing a disconnect between the company’s prospects and the valuation.
  • Noting that Hims & Hers (HIMS) is set to expand at over 78% CAGR in 2019–2023E, analyst Jonna Kim argues that the company’s $1.2B revenue target for 2025, indicating over 22% CAGR, "implies a significant slowdown."

Update - July 13, 2023

Kinda of a joke short report on Hims & Hers today, any stock could face a 25% hit. Heck, we view Apple as having the potential for 50% downside. The stock has bounced off strong support here. 

-Hims & Hers Health (NYSE:HIMS) ticked down 1% amid a new short call from Spruce Point Research.
-Spruce Point sees potential for Hims & Hers (HIMS) shares to fall 25% to 40% to $5.20–$6.50 per share, according to the new report.

Finviz Chart

Original article posted on June 12 

  • Hims & Hers plunged after Q2 adjusted EBITDA guidance disappointed Wall Street.
  • The online health and wellness company has massive growth opportunities ahead and continues investing aggressively in marketing to build its subscriber base.
  • HIMS stock is a bargain below 2x '24 sales targets for a company forecasted to maintain 25% growth while constantly providing conservative estimates.
Despite impressive numbers, Hims & Hers Health (NYSE:HIMS) has dipped the last month. The online health and wellness platform continues to produce the growth most companies can only dream about, but the stock market wants actual

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders